Literature DB >> 19584703

Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery.

Olena Stepanyuk1, Tom S Chiang, Lisa L Dever, Sandra L Paez, Sharon M Smith, George Perez, Robert H K Eng.   

Abstract

We reviewed the effect of adding maraviroc on CD4 cell counts in nine patients on antiretroviral therapy with full viral suppression but impaired CD4 cell recovery. There were no significant differences in changes in CD4 cell count, percentage of CD4 cells, or in the ratio of CD4/CD8 cells at 30 days and 25 weeks of maraviroc therapy. Plasma endotoxin levels measured in four patients before and during maraviroc treatment also showed no significant differences.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584703     DOI: 10.1097/QAD.0b013e32832f3c65

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

1.  Chemokine receptor CCR5 correlates with functional CD8+ T cells in SIV-infected macaques and the potential effects of maraviroc on T-cell activation.

Authors:  Xiaolei Wang; Kasi E Russell-Lodrigue; Marion S Ratterree; Ronald S Veazey; Huanbin Xu
Journal:  FASEB J       Date:  2019-04-29       Impact factor: 5.191

Review 2.  Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Authors:  Babafemi Taiwo; Robert L Murphy; Christine Katlama
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

3.  Treating HIV-1 Infection: What Might the Future Hold?

Authors:  Mathias Lichterfeld; Kimon C Zachary
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

4.  Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc.

Authors:  Eva Poveda; Vincent Soriano
Journal:  HIV AIDS (Auckl)       Date:  2010-03-19

5.  Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.

Authors:  Steven F L van Lelyveld; Julia Drylewicz; Maaike Krikke; Ellen M Veel; Sigrid A Otto; Clemens Richter; Robin Soetekouw; Jan M Prins; Kees Brinkman; Jan Willem Mulder; Frank Kroon; Ananja Middel; Jori Symons; Annemarie M J Wensing; Monique Nijhuis; José A M Borghans; Kiki Tesselaar; Andy I M Hoepelman
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

Review 6.  Maraviroc: a review of its use in HIV infection and beyond.

Authors:  Shawna M Woollard; Georgette D Kanmogne
Journal:  Drug Des Devel Ther       Date:  2015-10-01       Impact factor: 4.162

7.  Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.

Authors:  Stefano Rusconi; Paola Vitiello; Fulvio Adorni; Elisa Colella; Emanuele Focà; Amedeo Capetti; Paola Meraviglia; Clara Abeli; Stefano Bonora; Marco D'Annunzio; Antonio Di Biagio; Massimo Di Pietro; Luca Butini; Giancarlo Orofino; Manuela Colafigli; Gabriella d'Ettorre; Daniela Francisci; Giustino Parruti; Alessandro Soria; Anna Rita Buonomini; Chiara Tommasi; Silvia Mosti; Francesca Bai; Silvia Di Nardo Stuppino; Manuela Morosi; Marco Montano; Pamela Tau; Esther Merlini; Giulia Marchetti
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

8.  High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C.

Authors:  Sanjay Pujari; Sunil Gaikwad; Vivek Bele; Kedar Joshi; Digamber Dabhade
Journal:  J Int Assoc Provid AIDS Care       Date:  2018 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.